Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8

1.

Chimeric Antigen Receptor-Modified T Cell Therapy in Multiple Myeloma: Beyond B Cell Maturation Antigen.

Timmers M, Roex G, Wang Y, Campillo-Davo D, Van Tendeloo VFI, Chu Y, Berneman ZN, Luo F, Van Acker HH, Anguille S.

Front Immunol. 2019 Jul 16;10:1613. doi: 10.3389/fimmu.2019.01613. eCollection 2019. Review.

2.

Dendritic Cell-Based Immunotherapy of Acute Myeloid Leukemia.

Van Acker HH, Versteven M, Lichtenegger FS, Roex G, Campillo-Davo D, Lion E, Subklewe M, Van Tendeloo VF, Berneman ZN, Anguille S.

J Clin Med. 2019 Apr 27;8(5). pii: E579. doi: 10.3390/jcm8050579. Review.

3.

Efficient and Non-genotoxic RNA-Based Engineering of Human T Cells Using Tumor-Specific T Cell Receptors With Minimal TCR Mispairing.

Campillo-Davo D, Fujiki F, Van den Bergh JMJ, De Reu H, Smits ELJM, Goossens H, Sugiyama H, Lion E, Berneman ZN, Van Tendeloo V.

Front Immunol. 2018 Nov 7;9:2503. doi: 10.3389/fimmu.2018.02503. eCollection 2018.

4.

A versatile T cell-based assay to assess therapeutic antigen-specific PD-1-targeted approaches.

Versteven M, Van den Bergh JMJ, Broos K, Fujiki F, Campillo-Davo D, De Reu H, Morimoto S, Lecocq Q, Keyaerts M, Berneman Z, Sugiyama H, Van Tendeloo VFI, Breckpot K, Lion E.

Oncotarget. 2018 Jun 12;9(45):27797-27808. doi: 10.18632/oncotarget.25591. eCollection 2018 Jun 12.

5.

The role of the common gamma-chain family cytokines in γδ T cell-based anti-cancer immunotherapy.

Van Acker HH, Campillo-Davo D, Roex G, Versteven M, Smits EL, Van Tendeloo VF.

Cytokine Growth Factor Rev. 2018 Jun;41:54-64. doi: 10.1016/j.cytogfr.2018.05.002. Epub 2018 May 16. Review.

PMID:
29773448
6.

An MIF Promoter Polymorphism Is Associated with Susceptibility to Pulmonary Arterial Hypertension in Diffuse Cutaneous Systemic Sclerosis.

Bossini-Castillo L, Campillo-Davó D, López-Isac E, Carmona FD, Simeon CP, Carreira P, Callejas-Rubio JL, Castellví I, Fernández-Nebro A, Rodríguez-Rodríguez L, Rubio-Rivas M, García-Hernández FJ, Madroñero AB, Beretta L, Santaniello A, Lunardi C, Airó P, Hoffmann-Vold AM, Kreuter A, Riemekasten G, Witte T, Hunzelmann N, Vonk MC, Voskuyl AE, de Vries-Bouwstra J, Shiels P, Herrick A, Worthington J, Radstake TRDJ, Martin J; Spanish Scleroderma Group.

J Rheumatol. 2017 Oct;44(10):1453-1457. doi: 10.3899/jrheum.161369. Epub 2017 Jul 1.

PMID:
28668810
7.

The antihypertensive drug hydralazine activates the intrinsic pathway of apoptosis and causes DNA damage in leukemic T cells.

Ruiz-Magaña MJ, Martínez-Aguilar R, Lucendo E, Campillo-Davo D, Schulze-Osthoff K, Ruiz-Ruiz C.

Oncotarget. 2016 Apr 19;7(16):21875-86. doi: 10.18632/oncotarget.7871.

8.

Influence of TYK2 in systemic sclerosis susceptibility: a new locus in the IL-12 pathway.

López-Isac E, Campillo-Davo D, Bossini-Castillo L, Guerra SG, Assassi S, Simeón CP, Carreira P, Ortego-Centeno N, García de la Peña P; Spanish Scleroderma Group, Beretta L, Santaniello A, Bellocchi C, Lunardi C, Moroncini G, Gabrielli A, Riemekasten G, Witte T, Hunzelmann N, Kreuter A, Distler JH, Voskuyl AE, de Vries-Bouwstra J, Herrick A, Worthington J, Denton CP, Fonseca C, Radstake TR, Mayes MD, Martín J.

Ann Rheum Dis. 2016 Aug;75(8):1521-6. doi: 10.1136/annrheumdis-2015-208154. Epub 2015 Sep 2.

Supplemental Content

Loading ...
Support Center